IP Library Granted Patent US 8,236,302
Granted Patent B2
US 8,236,302 · App. 12/757,006 · Granted Aug 7, 2012

Compositions and methods of using chondroitinase ABCI mutants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,236,302
App. No.
12/757,006
Granted
Aug 7, 2012
Kind
B2
Abstract

One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.

Claims (13)

1. An isolated mutant chondroitinase ABCI enzyme comprising the amino acid sequence of SEQ ID NO: 3.

2. A method of treating a central nervous system injury comprising administering a therapeutically effective amount of an isolated mutant chondroitinase ABCI enzyme comprising the amino acid sequence of SEQ ID NO: 3.

3. The method of claim 2 , wherein the enzyme is administered following a contusion injury to the central nervous system.

4. The method of claim 2 , wherein the enzyme is administered following a non-contusion injury to the central nervous system.

5. The method of claim 2 , wherein the enzyme is administered following a spinal cord injury.

6. The method of claim 2 , wherein the enzyme is administered locally.

7. The method of claim 6 , wherein the local administration is selected from intrathecal and topical administration.

8. A method of promoting neuronal outgrowth comprising administering a therapeutically effective amount of an isolated mutant chondroitinase ABCI enzyme comprising the amino acid sequence of SEQ ID NO: 3.

9. The method of claim 8 , wherein the enzyme is administered following a contusion injury to the central nervous system.

10. The method of claim 8 , wherein the enzyme is administered following a non-contusion injury to the central nervous system.

11. The method of claim 8 , wherein the enzyme is administered following a spinal cord injury.

12. The method of claim 8 , wherein the enzyme is administered locally.

13. The method of claim 12 , wherein the local administration is selected from intrathecal and topical administration.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2010
From: CAGGIANO, ANTHONY O.; IACI, JENNIFER; VECCHIONE, ANDREA; MARKENSOHN, ELIZABETH
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 024208/0123 →